Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.34 |
| ▸ | F7 | P08709 | 2/20 | 0.34 |
| ▸ | F3 | P13726 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765440 | 0.91 | F7 (0.39) | F2F7F3MAPK1PRSS1 | |
| SCHEMBL30765751 | 0.90 | F3 (0.34) | F2F3MAPK1PRSS1PRSS2 | |
| SCHEMBL30765681 | 0.88 | F7 (0.33) | F2F7F3PRSS1PRSS2 | |
| SCHEMBL30765736 | 0.88 | PDE2A (0.38) | F2F7F3MAPK1PRSS1 | |
| SCHEMBL30765462 | 0.86 | MAPK1 (0.35) | F2F7MAPK1PRSS1 | |
| SCHEMBL30765686 | 0.85 | F2 (0.35) | F2F3MAPK1LMNA | |
| SCHEMBL30765728 | 0.84 | MAPK1 (0.38) | F2MAPK1PRSS1 | |
| SCHEMBL30765595 | 0.84 | F3 (0.35) | F2F3MAPK1PRSS1PRSS2 | |
| SCHEMBL30765885 | 0.83 | MAPK1 (0.34) | F2F3MAPK1PRSS1PRSS2 | |
| SCHEMBL30765625 | 0.82 | F2 (0.36) | F2F3MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |